Literature DB >> 2473472

Interleukin 3 activates human blood basophils via high-affinity binding sites.

P Valent1, J Besemer, M Muhm, O Majdic, K Lechner, P Bettelheim.   

Abstract

Pure populations of human basophilic granulocytes were obtained from chronic myeloid leukemia (CML) blood by negative selection using a mixture of monoclonal antibodies and complement. 125I-radiolabeled recombinant human interleukin 3 (rhIL-3) bound to purified basophils in a specific manner. Quantitative binding studies and Scatchard plot analyses performed on samples from two donors revealed the presence of a single class of high-affinity IL-3 binding sites (500 and 2100 sites per cell; dissociation constant at equilibrium, 230 and 160 pmol/liter, respectively). Purified CML basophils maintained in suspension in the presence of rhIL-3 (100 units/ml) incorporated up to 12 times more [3H]thymidine than basophils in control cultures. Furthermore, after preincubation in vitro with rhIL-3 (100 units/ml) for 30 min, normal blood basophils released 2- to 3-fold more histamine than basophils pretreated with control medium when exposed to various concentrations of an anti-IgE antibody. Together, these results show that rhIL-3 binds to a specific receptor on blood basophils and is a regulator of basophil function.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2473472      PMCID: PMC297659          DOI: 10.1073/pnas.86.14.5542

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  Mast cell typing: demonstration of a distinct hematopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes.

Authors:  P Valent; L K Ashman; W Hinterberger; F Eckersberger; O Majdic; K Lechner; P Bettelheim
Journal:  Blood       Date:  1989-05-15       Impact factor: 22.113

2.  Interleukin-3 is a differentiation factor for human basophils.

Authors:  P Valent; G Schmidt; J Besemer; P Mayer; G Zenke; E Liehl; W Hinterberger; K Lechner; D Maurer; P Bettelheim
Journal:  Blood       Date:  1989-05-15       Impact factor: 22.113

3.  Identification of gamma-E-antibodies as a carrier of reaginic activity.

Authors:  K Ishizaka; T Ishizaka
Journal:  J Immunol       Date:  1967-12       Impact factor: 5.422

4.  Identification of basophil granulocytes as a site of allergic histamine release.

Authors:  T Ishizaka; R De Bernardo; H Tomioka; L M Lichtenstein; K Ishizaka
Journal:  J Immunol       Date:  1972-04       Impact factor: 5.422

5.  Development of mast cells in vitro. II. Biologic function of cultured mast cells.

Authors:  T Ishizaka; T Adachi; K Ishizaka
Journal:  J Immunol       Date:  1977-01       Impact factor: 5.422

6.  A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells.

Authors:  T Uchiyama; S Broder; T A Waldmann
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

7.  Myeloid differentiation antigen defined by a monoclonal antibody.

Authors:  O Majdic; K Liszka; D Lutz; W Knapp
Journal:  Blood       Date:  1981-12       Impact factor: 22.113

8.  Human macrophage maturation and heterogeneity: analysis with a newly generated set of monoclonal antibodies to differentiation antigens.

Authors:  R Andreesen; K J Bross; J Osterholz; F Emmrich
Journal:  Blood       Date:  1986-05       Impact factor: 22.113

9.  Enhancement of IgE-mediated histamine release from human basophils by immune-specific lymphokines.

Authors:  S Ida; J J Hooks; R P Siraganian; A L Notkins
Journal:  Clin Exp Immunol       Date:  1980-08       Impact factor: 4.330

10.  Monoclonal antibodies to human erythrocytes.

Authors:  D J Anstee; P A Edwards
Journal:  Eur J Immunol       Date:  1982-03       Impact factor: 5.532

View more
  31 in total

1.  Regulation of human basophil activation; the role of Na+ and Ca2+ in IL-3-induced potentiation of IgE-mediated histamine release from human basophils.

Authors:  F Beauvais; K Echasserieau; C Burtin; J Benveniste
Journal:  Clin Exp Immunol       Date:  1994-01       Impact factor: 4.330

2.  Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy.

Authors:  S Vrtala; K Hirtenlehner; L Vangelista; A Pastore; H G Eichler; W R Sperr; P Valent; C Ebner; D Kraft; R Valenta
Journal:  J Clin Invest       Date:  1997-04-01       Impact factor: 14.808

Review 3.  Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome.

Authors:  Peter Valent; Cem Akin; Patrizia Bonadonna; Karin Hartmann; Knut Brockow; Marek Niedoszytko; Boguslaw Nedoszytko; Frank Siebenhaar; Wolfgang R Sperr; Joanna N G Oude Elberink; Joseph H Butterfield; Ivan Alvarez-Twose; Karl Sotlar; Andreas Reiter; Hanneke C Kluin-Nelemans; Olivier Hermine; Jason Gotlib; Sigurd Broesby-Olsen; Alberto Orfao; Hans-Peter Horny; Massimo Triggiani; Michel Arock; Lawrence B Schwartz; Dean D Metcalfe
Journal:  J Allergy Clin Immunol Pract       Date:  2019-02-05

Review 4.  Proposed diagnostic criteria and classification of basophilic leukemias and related disorders.

Authors:  P Valent; K Sotlar; K Blatt; K Hartmann; A Reiter; I Sadovnik; W R Sperr; P Bettelheim; C Akin; K Bauer; T I George; E Hadzijusufovic; D Wolf; J Gotlib; F-X Mahon; D D Metcalfe; H-P Horny; M Arock
Journal:  Leukemia       Date:  2017-01-16       Impact factor: 11.528

Review 5.  Cytokine-induced human basophil/mast cell growth and differentiation in vitro.

Authors:  J A Denburg
Journal:  Springer Semin Immunopathol       Date:  1990

6.  Differential response of human basophils and mast cells to recombinant chemokines.

Authors:  W Füreder; H Agis; H Semper; F Keil; U Maier; M R Müller; K Czerwenka; H Höfler; K Lechner; P Valent
Journal:  Ann Hematol       Date:  1995-05       Impact factor: 3.673

7.  Identification of basophils as a major source of hepatocyte growth factor in chronic myeloid leukemia: a novel mechanism of BCR-ABL1-independent disease progression.

Authors:  Sabine Cerny-Reiterer; Viviane Ghanim; Gregor Hoermann; Karl J Aichberger; Harald Herrmann; Leonhard Muellauer; Andreas Repa; Christian Sillaber; Andrew F Walls; Matthias Mayerhofer; Peter Valent
Journal:  Neoplasia       Date:  2012-07       Impact factor: 5.715

8.  Vaccination with genetically engineered allergens prevents progression of allergic disease.

Authors:  V Niederberger; F Horak; S Vrtala; S Spitzauer; M-T Krauth; P Valent; J Reisinger; M Pelzmann; B Hayek; M Kronqvist; G Gafvelin; H Grönlund; A Purohit; R Suck; H Fiebig; O Cromwell; G Pauli; M van Hage-Hamsten; R Valenta
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-13       Impact factor: 11.205

Review 9.  Why clinicians should be interested in interleukin-3.

Authors:  P Valent; K Geissler; C Sillaber; K Lechner; P Bettelheim
Journal:  Blut       Date:  1990-12

10.  Acute side effects of homologous interleukin-3 in rhesus monkeys.

Authors:  F C van Gils; A H Mulder; C van den Bos; H Burger; R W van Leen; G Wagemaker
Journal:  Am J Pathol       Date:  1993-12       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.